Medical treatments for incomplete miscarriage: Cochrane systematic review
Assessed as up to date: 2016/05/13
Miscarriage occurs in 10% to 15% of pregnancies. The traditional treatment, after miscarriage, has been to perform surgery to remove any remaining placental tissues in the uterus ('evacuation of uterus'). However, medical treatments, or expectant care (no treatment), may also be effective, safe, and acceptable.Objectives
To assess the effectiveness, safety, and acceptability of any medical treatment for incomplete miscarriage (before 24 weeks).Search methods
We searched Cochrane Pregnancy and Childbirth's Trials Register (13 May 2016) and reference lists of retrieved papers.Selection criteria
We included randomised controlled trials comparing medical treatment with expectant care or surgery, or alternative methods of medical treatment. We excluded quasi-randomised trials.Data collection and analysis
Two review authors independently assessed the studies for inclusion, assessed risk of bias, and carried out data extraction. Data entry was checked. We assessed the quality of the evidence using the GRADE approach.Main results
We included 24 studies (5577 women). There were no trials specifically of miscarriage treatment after 13 weeks' gestation.
Three trials involving 335 women compared misoprostol treatment (all vaginally administered) with expectant care. There was no difference in complete miscarriage (average risk ratio (RR) 1.23, 95% confidence interval (CI) 0.72 to 2.10; 2 studies, 150 women, random-effects; very low-quality evidence), or in the need for surgical evacuation (average RR 0.62, 95% CI 0.17 to 2.26; 2 studies, 308 women, random-effects; low-quality evidence). There were few data on 'deaths or serious complications'. For unplanned surgical intervention, we did not identify any difference between misoprostol and expectant care (average RR 0.62, 95% CI 0.17 to 2.26; 2 studies, 308 women, random-effects; low-quality evidence).
Sixteen trials involving 4044 women addressed the comparison of misoprostol (7 studies used oral administration, 6 studies used vaginal, 2 studies sublingual, 1 study combined vaginal + oral) with surgical evacuation. There was a slightly lower incidence of complete miscarriage with misoprostol (average RR 0.96, 95% CI 0.94 to 0.98; 15 studies, 3862 women, random-effects; very low-quality evidence) but with success rate high for both methods. Overall, there were fewer surgical evacuations with misoprostol (average RR 0.05, 95% CI 0.02 to 0.11; 13 studies, 3070 women, random-effects; very low-quality evidence) but more unplanned procedures (average RR 5.03, 95% CI 2.71 to 9.35; 11 studies, 2690 women, random-effects; low-quality evidence). There were few data on 'deaths or serious complications'. Nausea was more common with misoprostol (average RR 2.50, 95% CI 1.53 to 4.09; 11 studies, 3015 women, random-effects; low-quality evidence). We did not identify any difference in women's satisfaction between misoprostol and surgery (average RR 1.00, 95% CI 0.99 to 1.00; 9 studies, 3349 women, random-effects; moderate-quality evidence). More women had vomiting and diarrhoea with misoprostol compared with surgery (vomiting: average RR 1.97, 95% CI 1.36 to 2.85; 10 studies, 2977 women, random-effects; moderate-quality evidence; diarrhoea: average RR 4.82, 95% CI 1.09 to 21.32; 4 studies, 757 women, random-effects; moderate-quality evidence).
Five trials compared different routes of administration, or doses, or both, of misoprostol. There was no clear evidence of one regimen being superior to another.
Limited evidence suggests that women generally seem satisfied with their care. Long-term follow-up from one included study identified no difference in subsequent fertility between the three approaches.Authors' conclusions
The available evidence suggests that medical treatment, with misoprostol, and expectant care are both acceptable alternatives to routine surgical evacuation given the availability of health service resources to support all three approaches. Further studies, including long-term follow-up, are clearly needed to confirm these findings. There is an urgent need for studies on women who miscarry at more than 13 weeks' gestation.
Kim Caron, Barnard Sharmani, Neilson James P, Hickey Martha, Vazquez Juan C, Dou Lixia
Medical treatments for incomplete miscarriage
What is the issue?
Miscarriage is when a pregnant woman loses her baby before the baby would be considered able to survive outside the womb, i.e. before 24 weeks' gestation. Miscarriage occurs in about 10% to 15% of pregnancies and the signs are bleeding, usually with some abdominal pain and cramping. The traditional management of miscarriage was surgery but this Cochrane Review asks if medical treatments can be another management option for the woman.
Why is this important?
The cause of miscarriage is often unknown, but most are likely to be due to abnormalities in the baby’s chromosomes. Women experiencing miscarriage may be quite distressed, and there can be feelings of emptiness, guilt, and failure. Fathers can also be affected emotionally. Traditionally, surgery (curettage or vacuum aspiration) has been the treatment used to remove any retained tissue and it is quick to perform. It has now been suggested that medical treatments (usually misoprostol) may be as effective and may carry less risk of infection.
What evidence did we find?
We searched for evidence on 13 May 2016 and identified 24 studies involving 5577 women, and all these studies were of women at less than 13 weeks' gestation. There were a number of different ways of giving the drugs and so there are limited data for each comparison.
Overall, the review found no real difference in the success between misoprostol and waiting for spontaneous miscarriage (expectant care), nor between misoprostol and surgery. The overall success rate of treatment (misoprostol and surgery) was over 80% and sometimes as high as 99%, and one study identified no difference in subsequent fertility between methods of medication, surgery or expectant management. Vaginal misoprostol was compared with oral misoprostol in one study which found no difference in success, but there was an increase in the incidence of diarrhoea with oral misoprostol. However, women on the whole seemed happy with their care, whichever treatment they were given.
What does this mean?
The review suggests that misoprostol or waiting for spontaneous expulsion of fragments are important alternatives to surgery, but women should be offered an informed choice. Further studies are clearly needed to confirm these findings and should include long-term follow-up. There is an urgent need for studies on women who miscarry at more than 13 weeks' gestation.
Implications for practice
Although it would be critical to have more data, the current evidence suggests there appears to be no major differences, other than avoiding surgery, between misoprostol, expectant care, and surgery in the treatment of incomplete miscarriage for women of less than 13 weeks' gestation. Avoiding surgery has considerable benefits in terms of reducing adverse effects (although these were not fully assessed systematically in the included studies) and is particularly beneficial in low-income countries. We identified some differences in nausea, vomiting, and diarrhoea with the use of misoprostol which can be taken into account when counselling women on the treatment options.
Implications for research
There is an urgent need for studies to assess medical interventions for incomplete miscarriage for women between 13 to 24 weeks' gestation, as currently there are no trials to guide practice. Multicentre trials would seem appropriate to give sufficient size to provide sound evidence.
There is a need for more trials comparing the use of medical treatments, by the various routes, with expectant care and surgery to confirm or refute these findings for women less than 13 weeks' gestation. This should provide more evidence on the effectiveness and adverse effects, so women can be provided with better information in order to support their choices. Future trials should separate women with non-viable pregnancies prior to miscarriage, from those with incomplete miscarriages.
Women's views and quality of life measures should be assessed alongside the clinical outcome in any future trials. These trials should be large enough to provide definitive findings and should assess the important outcomes identified in this review.Get full text at The Cochrane Library
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.